The Supreme Court finally published its decision in the case of Association for Molecular Pathology v. Myriad Genetics, a case that seemed to hover over the landscape of life science patents for an eternity. We might be tempted to think the decision shuts the door on a very contentious area of patent law. After all, we now know isolated DNA is not patentable, but complementary DNA is. So that’s it, right? Wrong. In fact, at least one observer believes the decision may collapse at some point. Richard Gilly...